# US 2021/0277072 A1 · Plant-derived elastin binding protein ligands and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277072 A1
- Document ID: US20210277072A1
- Status: Published application
- Kind: A1
- Application number: 17/071,341
- Filed: 2020-10-15
- Published: 2021-09-09
- Earliest claimed: 2005-04-15
- Assignees: Elastogenesis, LLC; The Hospital for Sick Children
- Applicants: Elastogenesis, LLC; The Hospital for Sick Children
- Inventors: Felipe JIMENEZ; Thomas MITTS; Aleksander HINEK
- Web page: https://patentgrep.com/patent/US20210277072A1

## CPC

- C07K 14/415: from plants
- A61K 8/19: containing inorganic ingredients
- A61K 8/645: {Proteins of vegetable origin; Derivatives or degradation products thereof}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 33/26: Iron; Compounds thereof
- A61K 33/32: Manganese; Compounds thereof
- A61K 33/34: Copper; Compounds thereof
- A61K 38/168: {from plants}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 19/00: Preparations for care of the skin
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2800/74: Biological properties of particular ingredients
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.

## Claims

### Claim 1

A synthetic sextapeptide comprising the sequence X1-X2-X3-X4-X5-X6 (SEQ ID NO: 17), wherein:
X1 is a mimetic of V or a mimetic of I;
X2 is a mimetic of G;
X3 is a mimetic of A or a mimetic of L;
X4 is a mimetic of M or a mimetic of S;
X5 is a mimetic of P; and
X6 is a mimetic of G.

### Claim 2 (depends on 1)

The synthetic sextapeptide of claim 1, wherein the mimetic amino acid has one or more side chains replaced with a side chain selected from the group consisting of alkyl, lower alkyl, cyclic 4-membered alkyl, cyclic 5-membered alkyl, cyclic 6-membered alkyl, cyclic 7-membered alkyl, amide, amide lower alkyl, amide di (lower alkyl), lower alkoxy, hydroxy, carboxy and the lower ester derivatives thereof, and 4-membered heterocyclics, 5-membered heterocyclics, 6-membered heterocyclics, to 7-membered heterocyclics.

### Claim 3 (depends on 1)

A composition comprising the synthetic sextapeptide of claim 1.

### Claim 4 (depends on 3)

The composition of claim 3, further comprising a manganese compound, a trivalent iron compound, a sodium compound, a copper compound, an antioxidant, an additive, an excipient, or a combination thereof.

### Claim 5 (depends on 3)

The composition of claim 3, wherein the composition stimulates elastogenesis.

### Claim 6 (depends on 3)

The composition of claim 3, wherein the composition is used to enhance wound healing or treat cutaneous hypertrophic scars.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the composition is applied to the skin of a subject, and wherein the skin is selected from the group consisting of face, arms, legs, chest, and neck.

### Claim 8 (depends on 3)

The composition of claim 3, wherein the composition is a solution, a cream, an emulsion, a gel, a solid, or an aerosol.

### Claim 9

A synthetic acetylated sextapeptide comprising the sequence X1-X2-X3-X4-X5-X6 (SEQ ID NO: 3), wherein:
X1 is a V or I;
X2 is G;
X3 is A or L;
X4 is M or S;
X5 is P; and
X6 is G, and
wherein acetylation is at N-terminus.

### Claim 10 (depends on 9)

The synthetic acetylated sextapeptide of claim 9, wherein the synthetic acetylated sextapeptide is selected from the group consisting of acetylated VGAMPG (SEQ ID NO. 4), acetylated VGLSPG (SEQ ID NO. 5), acetylated IGAMPG (SEQ ID NO. 6), and acetylated IGLSPG (SEQ ID NO. 7).

### Claim 11 (depends on 9)

A composition comprising the synthetic acetylated sextapeptide of claim 9.

### Claim 12 (depends on 11)

The composition of claim 11, further comprising a manganese compound, a trivalent iron compound, a sodium compound, a copper compound, an antioxidant, an additive, an excipient, or a combination thereof.

### Claim 13 (depends on 11)

The composition of claim 11, wherein the composition stimulates elastogenesis.

### Claim 14 (depends on 11)

The composition of claim 11, wherein the composition is used to enhance wound healing or treat cutaneous hypertrophic scars.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the composition is applied to the skin of a subject, and wherein the skin is selected from the group consisting of face, arms, legs, chest, and neck.

### Claim 16 (depends on 11)

The composition of claim 11, wherein the composition is a solution, a cream, an emulsion, a gel, a solid, or an aerosol.

### Claim 17

A synthetic linked sextapeptide comprising the sequence X1-X2-X3-X4-X5-X6-X7-X1-X2-X3-X4-X5-X6 (SEQ ID NO: 18), wherein:
X1 is a mimetic of V or a mimetic of I;
X2 is a mimetic of G;
X3 is a mimetic of A or a mimetic of L;
X4 is a mimetic of M or a mimetic of S;
X5 is a mimetic of P;
X6 is a mimetic of G; and
X7 is a linking moiety.

### Claim 18 (depends on 17)

The synthetic linked sextapeptide of claim 17, wherein the mimetic amino acid has one or more side chains replaced with a side chain selected from the group consisting of alkyl, lower alkyl, cyclic 4-membered alkyl, cyclic 5-membered alkyl, cyclic 6-membered alkyl, cyclic 7-membered alkyl, amide, amide lower alkyl, amide di (lower alkyl), lower alkoxy, hydroxy, carboxy and the lower ester derivatives thereof, and 4-membered heterocyclics, 5-membered heterocyclics, 6-membered heterocyclics, to 7-membered heterocyclics.

### Claim 19 (depends on 17)

The synthetic linked sextapeptide of claim 17, wherein the linking moiety is selected from the group consisting of an amino acid, alanine, a disulfide bond, a carbonyl moiety, a hydrocarbon moiety optionally substituted at one or more available carbon atoms with a lower alkyl substituent, a lysine residue, and a lysine amide.

### Claim 20 (depends on 17)

A composition comprising the synthetic linked sextapeptide of claim 17.

### Claim 21 (depends on 20)

The composition of claim 20, further comprising a manganese compound, a trivalent iron compound, a sodium compound, a copper compound, an antioxidant, an additive, an excipient, or a combination thereof.

### Claim 22 (depends on 20)

The composition of claim 20, wherein the composition stimulates elastogenesis.

### Claim 23 (depends on 20)

The composition of claim 20, wherein the composition is used to enhance wound healing or treat cutaneous hypertrophic scars.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the composition is applied to the skin of a subject, and wherein the skin is selected from the group consisting of face, arms, legs, chest, and neck.

### Claim 25 (depends on 20)

The composition of claim 20, wherein the composition is a solution, a cream, an emulsion, a gel, a solid, or an aerosol.

### Claim 26

A synthetic linked acetylated sextapeptide comprising the sequence X1-X2-X3-X4-X5-X6-X7-X1-X2-X3-X4-X5-X6 (SEQ ID NO: 16), wherein:
X1 is a V or I;
X2 is G;
X3 is A or L;
X4 is M or S;
X5 is P;
X6 is G, and
X7 is a linking moiety; and
wherein acetylation is at N-terminus.

### Claim 27 (depends on 26)

The synthetic linked acetylated sextapeptide of claim 26, wherein the synthetic acetylated sextapeptide is selected from the group consisting of acetylated VGAMPGAAAAAVGAMPG (SEQ ID NO. 8), acetylated VGLSPGAAAAAVGLSPG (SEQ ID NO. 9), acetylated VGVAPGAAAAAVGVAPG (SEQ ID NO. 10), acetylated IGAMPGAAAAAIGAMPG (SEQ ID NO. 11), acetylated IGLSPGAAAAAIGLSPG (SEQ ID NO. 12), and acetylated IGVAPGAAAAAIGVAPG (SEQ ID NO. 14).

### Claim 28 (depends on 26)

A composition comprising the synthetic linked acetylated sextapeptide of claim 26.

### Claim 29 (depends on 28)

The composition of claim 28, further comprising a manganese compound, a trivalent iron compound, a sodium compound, a copper compound, an antioxidant, an additive, an excipient, or a combination thereof.

### Claim 30 (depends on 28)

The composition of claim 28, wherein the composition stimulates elastogenesis.

### Claim 31 (depends on 28)

The composition of claim 28, wherein the composition is used to enhance wound healing or treat cutaneous hypertrophic scars.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the composition is applied to the skin of a subject, and wherein the skin is selected from the group consisting of face, arms, legs, chest, and neck.

### Claim 33 (depends on 28)

The composition of claim 28, wherein the composition is a solution, a cream, an emulsion, a gel, a solid, or an aerosol.
